Healthcare sector private equity firm Ampersand Capital Partners revealed on Thursday that it plans to acquire Vibalogics GmbH, a contract development and manufacturing organisation (CDMO) in Cuxhaven, Germany.
The financial terms of the agreement were not disclosed by the companies.
Ampersand said that its growth investment will be used to expand Vibalogics' capabilities to meet rapidly growing industry demand for the development and manufacturing of complex viral products.
Vibalogics offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies and vaccines. With a specific focus on viruses, live bacteria and aseptic processing, the company's 50 employees work in full compliance with international GMP standards in a BSL-2 classified state of the art, 27,000 sq ft (2,500 m2) facility in Cuxhaven, Germany.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine